查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586054

癌症單株抗體市場：按類型、應用和最終用戶分類 - 全球預測 2025-2030

Cancer Monoclonal Antibodies Market by Type (Chimeric, Human, Humanized), Application (Blood Cancer, Breast Cancer, Colorectal Cancer), End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

癌症單株抗體市場2023年估值為698.7億美元，預計2024年將達到786億美元，複合年成長率為12.89%，到2030年將達到1632.8億美元。

癌症單株抗體 (mAb) 是癌症治療的關鍵進展，其特點是標靶治療方法，可特異性攻擊癌細胞，同時保護健康組織。這種需求源於癌症盛行率的不斷上升以及對比化療和放射線治療等傳統治療方法更有效、毒性更低的治療方法的需求。單株抗體的應用涵蓋多種癌症類型，在乳癌、大腸癌、非何傑金氏淋巴瘤、肺癌等方面都有很大的效用。最終用途主要是參與精準醫療的醫院、專科診所和研究機構。根據市場洞察，抗體工程的技術進步、公共和私人研發投資的增加以及新治療方法的監管核准增加正在推動市場的強勁成長。機會比比皆是，包括將單株抗體整合到個人化醫療中、使用伴同性診斷進行患者分層，以及使用雙特異性單株抗體同時靶向多個抗原。主要挑戰包括高昂的開發成本、複雜的製造流程以及嚴格的監管要求，這些都可能阻礙中小企業進入市場。新興地區的意識和准入有限，以及生物相似藥競爭導致壟斷定價的可能性降低，也阻礙了市場成長。促進業務成長的創新技術包括改進抗體藥物複合體、利用人工智慧進行藥物發現以及免疫查核點抑制劑聯合治療的研究。為了利用新的商機，公司應專注於策略聯盟，在全球擴大臨床試驗，並倡導有利的報銷政策以增加獲得治療的機會。市場是動態的，其特點是技術快速進步和不斷變化的監管環境，需要靈活的策略和持續的適應。透過順應這些趨勢並解決開發和營運障礙，相關人員可以有效地利用癌症單株抗體不斷擴大的治療和商業性潛力。

主要市場統計
基準年[2023] 698.7億美元
預測年份 [2024] 786億美元
預測年份 [2030] 1632.8億美元
複合年成長率（%） 12.89%

市場動態：快速發展的癌症單株抗體市場的關鍵市場洞察

供需的動態交互作用正在改變癌症單株抗體市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 世界各地各種癌症的盛行率不斷上升
    • 人們越來越認知到癌症單株抗體可以改善和抑制免疫反應
    • 由於強大的管道，藥品核准增加
  • 市場限制因素
    • 單株抗體回收數量快速增加
  • 市場機會
    • 新型單株抗體臨床試驗增加
    • 癌症單株抗體開發的合作方法
  • 市場挑戰
    • 與單株抗體生產相關的監管和技術複雜性

波特五力：駕馭癌症單株抗體市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對癌症單株抗體市場的影響

外部宏觀環境因素在塑造癌症單株抗體市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解癌症單株抗體市場的競爭格局

對癌症單株抗體市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣癌症單株抗體市場供應商的績效評估

FPNV定位矩陣是評估癌症單株抗體市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了癌症單株抗體市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，癌症單株抗體市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地各種癌症的發生率正在上升
      • 提高對癌症單株抗體改善和抑制免疫反應的認知
      • 強大的管道和不斷增加的藥物核准數量
    • 抑制因素
      • 回收的單株抗體數量迅速增加
    • 機會
      • 新開發的單株抗體的臨床試驗增加
      • 開發癌症單株抗體的合作方法
    • 任務
      • 與單株抗體生產相關的監管和技術複雜性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章癌症單株抗體市場：依類型

  • 嵌合體
  • 人類
  • 人性化
  • 鼠

第7章癌症單株抗體市場：依應用分類

  • 血癌
  • 乳癌
  • 大腸直腸癌
  • 肝癌
  • 肺癌
  • 惡性黑色素瘤

第8章癌症單株抗體市場：依最終用戶分類

  • 醫院
  • 調查機構
  • 研究室

第9章美洲癌症單株抗體市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區癌症單株抗體市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲癌症單株抗體市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • Amgen, Inc.
  • Astrazeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bristol Myers Squibb Co.
  • Celldex Therapeutics, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GSK PLC
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Qiagen NV
  • Sanofi SA
  • Sartorius AG
  • Seagen Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-450A0628C5A8

The Cancer Monoclonal Antibodies Market was valued at USD 69.87 billion in 2023, expected to reach USD 78.60 billion in 2024, and is projected to grow at a CAGR of 12.89%, to USD 163.28 billion by 2030.

Cancer monoclonal antibodies (mAbs) represent a pivotal advancement in oncology, marked by their targeted therapeutic approach which specifically attacks cancer cells while sparing healthy tissues. Their necessity arises from the growing prevalence of cancer and the need for more effective, less toxic treatment alternatives compared to traditional options like chemotherapy and radiation. The application of mAbs spans numerous cancer types, with significant utility in breast, colorectal, non-Hodgkin's lymphoma, and lung cancers. End-use scope mainly involves hospitals, specialty clinics, and research institutes engaged in precision medicine. Market insights reveal robust growth driven by technological advancements in antibody engineering, rising public and private R&D investments, and increased regulatory approvals for new therapies. Opportunities abound with the integration of mAbs in personalized medicine, harnessing companion diagnostics for patient stratification, and utilizing bispecific monoclonal antibodies to target multiple antigens simultaneously. Key challenges include high development costs, complex manufacturing processes, and stringent regulatory requirements, which can impede smaller players from entering the market. Market growth is also hindered by limited awareness and access in emerging regions, alongside biosimilar competition decreasing monopoly pricing potential. Innovations poised for business growth lie in improving antibody-drug conjugates, leveraging artificial intelligence for drug discovery, and exploring immune checkpoint inhibitors combination therapies. To capitalize on emerging opportunities, companies should focus on strategic collaborations, expand clinical trials globally, and advocate for favorable reimbursement policies to enhance treatment accessibility. The market is dynamic, characterized by rapid technological progress and evolving regulatory landscapes, necessitating agile strategies and continuous adaptation. By aligning with these trends and tackling developmental and operational hurdles, stakeholders can leverage the expanding therapeutic and commercial potential of cancer monoclonal antibodies effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 69.87 billion
Estimated Year [2024] USD 78.60 billion
Forecast Year [2030] USD 163.28 billion
CAGR (%) 12.89%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Monoclonal Antibodies Market

The Cancer Monoclonal Antibodies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of different cancers worldwide
    • Growing awareness of cancer monoclonal antibodies to improve & suppress the immune responses
    • Increasing drug approvals along with a robust pipeline
  • Market Restraints
    • Surging number of withdrawals of monoclonal antibodies
  • Market Opportunities
    • Increasing clinical trials of newly developed monoclonal antibodies
    • Collaborative approach for development of cancer monoclonal antibodies
  • Market Challenges
    • Regulatory and technical complications associated with manufacture of monoclonal antibodies

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Monoclonal Antibodies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Monoclonal Antibodies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Monoclonal Antibodies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Monoclonal Antibodies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Monoclonal Antibodies Market

A detailed market share analysis in the Cancer Monoclonal Antibodies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Monoclonal Antibodies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Monoclonal Antibodies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Monoclonal Antibodies Market

A strategic analysis of the Cancer Monoclonal Antibodies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Monoclonal Antibodies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., Amgen, Inc., Astrazeneca PLC, Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bristol Myers Squibb Co., Celldex Therapeutics, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GSK PLC, Incyte Corporation, Johnson & Johnson, Merck & Co., Merck KGaA, Novartis AG, Pfizer Inc., Qiagen N.V., Sanofi S.A., Sartorius AG, Seagen Inc., Takara Bio Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Monoclonal Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Chimeric, Human, Humanized, and Murine.
  • Based on Application, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, and Melanoma.
  • Based on End-user, market is studied across Hospitals, Research Institutes, and Research Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of different cancers worldwide
      • 5.1.1.2. Growing awareness of cancer monoclonal antibodies to improve & suppress the immune responses
      • 5.1.1.3. Increasing drug approvals along with a robust pipeline
    • 5.1.2. Restraints
      • 5.1.2.1. Surging number of withdrawals of monoclonal antibodies
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing clinical trials of newly developed monoclonal antibodies
      • 5.1.3.2. Collaborative approach for development of cancer monoclonal antibodies
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory and technical complications associated with manufacture of monoclonal antibodies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Monoclonal Antibodies Market, by Type

  • 6.1. Introduction
  • 6.2. Chimeric
  • 6.3. Human
  • 6.4. Humanized
  • 6.5. Murine

7. Cancer Monoclonal Antibodies Market, by Application

  • 7.1. Introduction
  • 7.2. Blood Cancer
  • 7.3. Breast Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Liver Cancer
  • 7.6. Lung Cancer
  • 7.7. Melanoma

8. Cancer Monoclonal Antibodies Market, by End-user

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Research Institutes
  • 8.4. Research Laboratories

9. Americas Cancer Monoclonal Antibodies Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Monoclonal Antibodies Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Monoclonal Antibodies Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Agilent Technologies, Inc.
  • 3. Amgen, Inc.
  • 4. Astrazeneca PLC
  • 5. Bayer AG
  • 6. Becton, Dickinson and Company
  • 7. Bio-Rad Laboratories, Inc.
  • 8. Bristol Myers Squibb Co.
  • 9. Celldex Therapeutics, Inc.
  • 10. Eli Lilly and Company
  • 11. F. Hoffmann-La Roche AG
  • 12. Gilead Sciences, Inc.
  • 13. GSK PLC
  • 14. Incyte Corporation
  • 15. Johnson & Johnson
  • 16. Merck & Co.
  • 17. Merck KGaA
  • 18. Novartis AG
  • 19. Pfizer Inc.
  • 20. Qiagen N.V.
  • 21. Sanofi S.A.
  • 22. Sartorius AG
  • 23. Seagen Inc.
  • 24. Takara Bio Inc.
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANCER MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANCER MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER MONOCLONAL ANTIBODIES MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. CANCER MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. CANCER MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023